PreveCeutical Medical Inc. Announces Appointment of Dr. Makarand Jawadekar to its Board of Directors
Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the appointment of Dr. Makarand Jawadekar as a director of the Company and the resignation of Mr. Brian Harris as a director and the Vice President of Corporate Development of the Company, effective October 24, 2017.
Dr. Jawadekar completed his Ph.D. in Pharmaceutics at the University of Minnesota. He is currently an independent Pharma Professional and the owner of the pharmaceutical consulting company, Melinda Consulting LLC (“Melinda”). Prior to Melinda, Dr. Jawadekar worked at Pfizer Inc. for twenty-eight years, where he most recently acted as the Director of Portfolio Management. During his career, he was responsible for drug delivery technology assessments involving external drug delivery technologies. Dr. Jawadekar has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. In February 2011, he was awarded an honorary D.Sc. degree from DYP Mumbai University, upon the recommendation of the President of India.
“We are delighted to welcome Dr. Jawadekar to PreveCeutical’s board of directors,” said Stephen Van Deventer, Chairman and CEO of the Company. “His exceptional knowledge in drug delivery technologies and experience in the pharmaceutical industry will be of tremendous benefit to the Company.”
“It is a great honour to be invited to join the board of directors of PreveCeutical. Stephen has done a great job assembling a wonderful and talented team and it gives me pleasure to be a part of this esteemed board,” said Dr. Jawadekar. “I look forward to working with everyone and bring in synergies for a fruitful journey of innovation along with Dr. Herendra Parekh's research team at the University of Queensland in Australia.”
Dr. Jawadekar will continue as the Chief Scientific Officer of PreveCeutical, where his role is instrumental to the development of the Company’s innovative product portfolio.
Mr. Brian Harris has stepped down as director of the Company and the Vice President of Corporate Development to focus on other projects. Stephen Van Deventer, Chairman and CEO stated, “On behalf of the board of directors and management of the Company, I would like to thank Mr. Harris for his dedication to the Company and wish him all the best in his future endeavours”.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five Research and Development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.
For more information about PreveCeutical, please visit
www.PreveCeutical.com, follow us on Twitter:
http://twitter.com/PreveCeuticals and Facebook:
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman & CEO
For further information, please contact:
Director of Corporate Communications & Investor Relations
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including the Company's anticipated business plans, and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, complete its research programs as planned, obtain the financing required to carry out its planned future. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.